Genome Biologics

Executive Summary

Genome Biologics, a Munich-based private biotechnology company, operates as a contract research organization (CRO) specializing in predictive screening for cardiovascular drug development. Founded in 2017, the company leverages its proprietary TrueCardium® platform—a multicellular human cardiac organoid system—to provide cardiotoxicity testing, disease modeling, and multi-omics profiling services. By offering a more physiologically relevant human model than traditional animal or 2D cell cultures, Genome Biologics addresses a critical need in the pharmaceutical industry to improve drug safety and efficacy predictions early in development. The company serves pharmaceutical and biotech partners seeking to reduce late-stage attrition due to cardiovascular toxicity. With its advanced organoid technology, Genome Biologics is positioned to capture value from the growing demand for human-relevant in vitro models, especially as regulatory agencies increasingly encourage the use of New Approach Methodologies (NAMs). The company’s stage is Phase 2, indicating ongoing commercial validation and scaling of its services. Given the large market for cardiac safety testing and the trend toward animal-free testing, Genome Biologics has the potential to become a key partner for drug developers globally.

Upcoming Catalysts (preview)

• Q3 2026Major pharma partnership for cardiotoxicity screening40% success
• Q2 2026Publication of validation study in a top-tier journal60% success
• Q4 2026Expansion of service menu to include arrhythmia disease models50% success